# US 2024/0002822 A1 · Methods and compositions for modulating a genome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002822 A1
- Document ID: US20240002822A1
- Status: Published application
- Kind: A1
- Application number: 18/356,013
- Filed: 2023-07-20
- Published: 2024-01-04
- Earliest claimed: 2021-09-08
- Assignees: Flagship Pioneering Innovations VI, LLC
- Applicants: Flagship Pioneering Innovations VI, LLC
- Inventors: Robert Charles Altshuler; Anne Helen Bothmer; Cecilia Giovanna Silvia Cotta-Ramusino; Randi Michelle Kotlar; Ananya Ray; Nathaniel Roquet; Carlos Sanchez; Barrett Ethan Steinberg
- Web page: https://patentgrep.com/patent/US20240002822A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure provides, e.g., compositions, systems, and methods for targeting, editing, modifying, or manipulating a host cell's genome at one or more locations in a DNA sequence in a cell, tissue, or subject.

## Claims

### Claim 1

A gene modifying polypeptide comprising:
a reverse transcriptase (RT) domain having the sequence of SEQ ID NO: 8,113;
a Cas9 nickase domain, wherein the RT domain is C-terminal of the Cas9 nickase domain; and
a linker disposed between the RT domain and the Cas9 nickase domain, wherein the linker comprises a sequence of SEQ ID NO: 15,404.

### Claim 2 (depends on 1)

The gene modifying polypeptide of claim 1, wherein the Cas9 nickase domain is a SpyCas9 nickase domain.

### Claim 3 (depends on 1)

The gene modifying polypeptide of claim 1, wherein the Cas9 nickase domain comprises an N863A mutation.

### Claim 4 (depends on 1)

The gene modifying polypeptide of claim 1, wherein the Cas9 nickase domain comprises an amino acid sequence of SEQ ID NO: 11,096.

### Claim 5 (depends on 1)

The gene modifying polypeptide of claim 1, wherein the Cas9 nickase domain is an NmeCas9 domain.

### Claim 6 (depends on 1)

The gene modifying polypeptide of claim 1, wherein the Cas9 nickase domain is an St1Cas9 domain.

### Claim 7 (depends on 1)

The gene modifying polypeptide of claim 1, wherein the Cas9 nickase domain is a SauCas9 domain.

### Claim 8 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises a nuclear localization signal (NLS).

### Claim 9 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises a first NLS which is N-terminal of the Cas9 nickase domain.

### Claim 10 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises an NLS which is C-terminal of the RT domain.

### Claim 11 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises a first NLS which is N-terminal of the Cas9 nickase domain and a second NLS which is C-terminal of the RT domain.

### Claim 12 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises a first NLS which is N-terminal of the Cas9 nickase domain, wherein the first NLS comprises an amino acid sequence of
(SEQ ID NO: 11,095)
PAAKRVKLD.

### Claim 13 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises an NLS which is C-terminal of the RT domain and comprises an amino acid sequence of KRTADGSEFE (SEQ ID NO: 4650).

### Claim 14 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises an NLS which is C-terminal of the RT domain and comprises an amino acid sequence of
(SEQ ID NO: 4651)
KRTADGSEFESPKKKAKVE.

### Claim 15 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises a sequence of SEQ ID NO: 4000 which comprises a first NLS and the Cas9 nickase domain.

### Claim 16 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises an NLS having a sequence according to SEQ ID NO: 4649.

### Claim 17 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises a GG amino acid sequence between the Cas9 nickase domain and the linker.

### Claim 18 (depends on 11)

The gene modifying polypeptide of claim 11, which comprises an AG amino acid sequence between the RT domain and the second NLS.

### Claim 19 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises a GG amino acid sequence between the linker and the RT domain.

### Claim 20 (depends on 1)

The gene modifying polypeptide of claim 1, which comprises an amino acid sequence according to SEQ ID NO: 647.

### Claim 21 (depends on 1)

A nucleic acid molecule encoding the gene modifying polypeptide of claim 1.

### Claim 22 (depends on 21)

The nucleic acid molecule of claim 21, which comprises RNA.

### Claim 23 (depends on 1)

A cell comprising: i) the gene modifying polypeptide of claim 1 or ii) a nucleic acid encoding the gene modifying polypeptide.

### Claim 24 (depends on 1)

A system comprising:
i) the gene modifying polypeptide of claim 1, or a nucleic acid molecule encoding the gene modifying polypeptide, and
ii) a template RNA that comprises:
a) a gRNA spacer that is complementary to a portion of a target nucleic acid sequence;
b) a gRNA scaffold that binds the Cas9 nickase domain of the gene modifying polypeptide;
c) a heterologous object sequence; and
d) a primer binding site sequence.

### Claim 25 (depends on 24)

A lipid nanoparticle formulation comprising the system of claim 24.

### Claim 26 (depends on 24)

A method for modifying a target nucleic acid molecule in a cell, the method comprising contacting the cell with the system of claim 24, thereby modifying the target nucleic acid molecule.

### Claim 27

A gene modifying polypeptide comprising:
a reverse transcriptase (RT) domain having the sequence of Table 6;
a Cas9 nickase domain, wherein the RT domain is C-terminal of the Cas9 nickase domain; and
a linker disposed between the RT domain and the Cas9 nickase domain, wherein the linker comprises a sequence of Table 10,
wherein if the RT domain has an amino acid sequence according to SEQ ID NO:
8,113, the linker does not have an amino acid sequence according to SEQ ID NO:
15,404.

### Claim 28 (depends on 27)

A composition comprising:
a nucleic acid molecule encoding the gene modifying polypeptide of claim 27,
a cell comprising the gene modifying polypeptide, or
a cell comprising the nucleic acid encoding the gene modifying peptide.

### Claim 29 (depends on 27)

A system comprising:
i) the gene modifying polypeptide of claim 27, or a nucleic acid molecule encoding the gene modifying polypeptide, and
ii) a template RNA that comprises:
a) a gRNA spacer that is complementary to a portion of a target nucleic acid sequence;
b) a gRNA scaffold that binds the Cas9 nickase domain of the gene modifying polypeptide;
c) a heterologous object sequence; and
d) a primer binding site sequence.

### Claim 30 (depends on 29)

A method for modifying a target nucleic acid molecule in a cell, the method comprising contacting the cell with the system of claim 29, thereby modifying the target nucleic acid molecule.
